NASDAQ:GLMD Galmed Pharmaceuticals (GLMD) Stock Forecast, Price & News $4.30 -0.30 (-6.52%) (As of 04:17 PM ET) Add Compare Share Share Today's Range$4.30▼$4.6650-Day Range$4.32▼$7.0552-Week Range$3.43▼$14.18Volume5,363 shsAverage Volume17,806 shsMarket Capitalization$7.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Galmed Pharmaceuticals (NASDAQ:GLMD) StockGalmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.Read More Receive GLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address GLMD Stock News HeadlinesMay 25, 2023 | americanbankingnews.comGalmed Pharmaceuticals (GLMD) Set to Announce Earnings on FridayMay 25, 2023 | americanbankingnews.comGalmed Pharmaceuticals (GLMD) to Release Earnings on FridayMay 30, 2023 | Behind the Markets (Ad)WARNING: Do You Invest with these BanksTake a close look at the investment banks above. Because if you have stocks with any of these brokerages... These new political developments WILL affect you.May 25, 2023 | americanbankingnews.comGalmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.comMay 19, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)May 18, 2023 | americanbankingnews.comGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest UpdateMay 17, 2023 | thestreet.comWhy Galmed Pharmaceuticals (GLMD) Stock Is Surging TodayMay 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Galmed Pharmaceuticals (GLMD) and Haemonetics (HAE)May 30, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.May 9, 2023 | finance.yahoo.comGalmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)May 9, 2023 | americanbankingnews.comGalmed Pharmaceuticals (NASDAQ:GLMD) Research Coverage Started at StockNews.comMay 5, 2023 | msn.comWhy Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?May 4, 2023 | finance.yahoo.comGalmed Pharmaceuticals forms a Strategic Partnership with OnKaiApril 23, 2023 | americanbankingnews.comGalmed Pharmaceuticals (NASDAQ:GLMD) Receives New Coverage from Analysts at StockNews.comApril 18, 2023 | americanbankingnews.comGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Receives Average Rating of "Hold" from BrokeragesApril 16, 2023 | americanbankingnews.comGalmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.comMarch 29, 2023 | finance.yahoo.comGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022March 26, 2023 | americanbankingnews.comGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Given Consensus Rating of "Hold" by BrokeragesFebruary 17, 2023 | seekingalpha.comGLMD Galmed Pharmaceuticals Ltd.February 8, 2023 | finance.yahoo.comGalmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine SaltJanuary 6, 2023 | finance.yahoo.comCan Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?January 4, 2023 | marketwatch.comGalmed Pharmaceuticals Shares Up 9.2% on Data From Liver Treatment Aramchol StudyJanuary 4, 2023 | finance.yahoo.comGalmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with AramcholDecember 14, 2022 | finance.yahoo.comGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price RequirementSeptember 14, 2022 | finance.yahoo.comGalmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the UpgradeAugust 4, 2022 | finance.yahoo.comGalmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial ResultsJuly 7, 2022 | finance.yahoo.comGalmed's Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal ModelSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address GLMD Company Calendar Last Earnings3/29/2023Today5/30/2023Next Earnings (Estimated)5/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLMD CUSIPN/A CIK1595353 Webwww.galmedpharma.com Phone(723) 693-8448Fax972-3693-8447Employees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($10.4948) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,870,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-94.31% Return on Assets-76.78% Debt Debt-to-Equity RatioN/A Current Ratio4.76 Quick Ratio4.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.98 per share Price / Book0.58Miscellaneous Outstanding Shares1,680,000Free Float1,348,000Market Cap$7.83 million OptionableOptionable Beta1.12 Key ExecutivesAllen BaharaffChairman, President & Chief Executive OfficerGuy NehemyaChief Operating & Data Protection OfficerDoron CohenChief Financial OfficerLiat HayardenyChief Scientific OfficerNeta TobisDirector-Clinical AffairsKey CompetitorsAcelRx PharmaceuticalsNASDAQ:ACRXCan-Fite BioPharmaNYSE:CANFRedHill BiopharmaNASDAQ:RDHLGuardion Health SciencesNASDAQ:GHSICyclacel PharmaceuticalsNASDAQ:CYCCView All CompetitorsInstitutional OwnershipBVF Inc. ILSold 391,915 shares on 5/16/2023Ownership: 5.348%View All Institutional Transactions GLMD Stock - Frequently Asked Questions Should I buy or sell Galmed Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GLMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLMD, but not buy additional shares or sell existing shares. View GLMD analyst ratings or view top-rated stocks. How have GLMD shares performed in 2023? Galmed Pharmaceuticals' stock was trading at $7.50 at the start of the year. Since then, GLMD stock has decreased by 37.9% and is now trading at $4.66. View the best growth stocks for 2023 here. Are investors shorting Galmed Pharmaceuticals? Galmed Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 19,800 shares, an increase of 1,700.0% from the April 30th total of 1,100 shares. Based on an average trading volume of 23,100 shares, the days-to-cover ratio is currently 0.9 days. Currently, 1.4% of the shares of the stock are sold short. View Galmed Pharmaceuticals' Short Interest. When is Galmed Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 30th 2023. View our GLMD earnings forecast. How were Galmed Pharmaceuticals' earnings last quarter? Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced its quarterly earnings data on Wednesday, March, 29th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter. When did Galmed Pharmaceuticals' stock split? Galmed Pharmaceuticals's stock reverse split before market open on Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Galmed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP). What is Galmed Pharmaceuticals' stock symbol? Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD." Who are Galmed Pharmaceuticals' major shareholders? Galmed Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BVF Inc. IL (5.35%). How do I buy shares of Galmed Pharmaceuticals? Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Galmed Pharmaceuticals' stock price today? One share of GLMD stock can currently be purchased for approximately $4.66. How much money does Galmed Pharmaceuticals make? Galmed Pharmaceuticals (NASDAQ:GLMD) has a market capitalization of $7.83 million. The biopharmaceutical company earns $-17,870,000.00 in net income (profit) each year or ($10.4948) on an earnings per share basis. How can I contact Galmed Pharmaceuticals? Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The official website for the company is www.galmedpharma.com. The biopharmaceutical company can be reached via phone at (723) 693-8448, via email at investor.relations@galmedpharma.com, or via fax at 972-3693-8447. This page (NASDAQ:GLMD) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.